🔴 Boston Scientific is trading 11.23% down in pre-market after lowering its full-year outlook

Boston Scientific is trading 11.23% down in pre-market at $40.00 after its October 28, 2026, earnings report lowered its outlook.

• Third-quarter sales were $5.138 billion; adjusted EPS was $0.73.
• Full-year guidance calls for approximately 3.75% organic sales growth and adjusted EPS of $3.16–$3.18.
• Fourth-quarter sales are expected to decline 1%–3%; the company cited disruption from an August cybersecurity incident.